Gilead Sciences — May 7, 2026 release

May 7, 2026 3      Guidance and Outlook For the full year 2026, Gilead now expects: (in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low End High End Product sales $ 30,000  $ 30,400  Previously $29,600 to $30,000 Product sales excluding Veklury $ 29,400  $ 29,800  Previously $29,000 to $29,400 Veklury $ 600  $ 600  Unchanged Diluted (loss) earnings per share $ (3.25) $ (2.85) Previously $6.75 to $7.15 Non-GAAP diluted (loss) earnings per share $ (1.05) $ (0.65) Previously $8.45 to $8.85 As compared to our February guidance, our updated full year 2026 GAAP and non-GAAP diluted earnings per share guidance was reduced by approximately $9.50 due to the anticipated acquired IPR&D charges of $11.5 billion as well as financing costs related to the Arcellx, Inc. (“Arcellx”), Ouro Medicines, LLC (“Ouro”), and Tubulis GmbH (“Tubulis”) transactions discussed further below. Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below. Key Updates Since Our Last Quarterly Release Virology • Announced U.S. Food and Drug Administration (“FDA”) accepted New Drug Application for bictegravir and lenacapavir (“BIC/LEN”) for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 27, 2026. • Presented late-breaking Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), evalua